Federal Supply Schedule 36F79722D0202

CTI Biopharma Corp. was awarded a Federal Supply Schedule contract (36F79722D0202) by the Department of Veterans Affairs Veterans Integrated Service Network 12 on November 1, 2022, for the provision of drugs, pharmaceuticals, and hematology-related products under General Services Administration Schedule 65 I B (Pharmaceuticals and Drugs). The contract is a multiple-award vehicle with a ceiling value of $3,000,000 and an ultimate completion date of October 31, 2027. No set-aside was applied to this award, indicating full and open competition among eligible contractors. The contract supports the VA's mission to ensure the availability of critical medical supplies and therapeutic agents for veterans receiving care through the Veterans Integrated Service Network 12, which encompasses healthcare facilities serving a designated geographic region.

As a biopharmaceutical manufacturer specializing in targeted therapies for hematologic malignancies and blood-related diseases, CTI Biopharma is positioned to deliver innovative pharmaceutical solutions through this Federal Supply Schedule vehicle. Task orders or individual purchase orders issued against this contract would be placed by authorized VA contracting officers to procure specific drugs and hematology products as clinical needs arise across the Veterans Integrated Service Network 12 healthcare system. The Federal Supply Schedule structure enables the VA to leverage pre-negotiated pricing and established supply relationships while maintaining flexibility in ordering quantities and delivery schedules based on veteran patient populations and treatment requirements.